The aim of this study is to find a laboratory marker for overall survival in advanced cancer patients who were vaccinated with peptides based on pre-existing, peptide-specific CTL precursors in the circulation.
Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.
Department of Immunology, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, 67 Asahi-machi, Fukuoka, Kurume 830-0011, Japan. mine@med.kurume-u.ac.jp
